Tirofiban antithrombotics

Description Results NMA

Short-term death 4.54 [0.99; 20.78]

Short-term major bleeding 1.39 [0.57; 3.39]

Short-term non-fatal reinfarction 1.51 [0.25; 8.97]

Short-term urgent target vessel revascularisation ∞ [NaN; ∞]

Final TIMI 3 flow 0.99 [0.93; 1.05]

Initial TIMI 3 flow 1.28 [0.86; 1.91]

Initial TIMI 3 flow 3.20 [1.27; 8.07]

Short-term death 1.00 [0.06; 15.55]

Short-term major bleeding 1.00 [0.06; 15.55]

Short-term non-fatal reinfarction 0.00 [0.00; NaN]

Short-term urgent target vessel revascularisation 0.00 [0.00; NaN]

Final TIMI 3 flow 1.00 [0.89; 1.12]

Short-term death 0.00 [0.00; NaN]

Short-term major bleeding 1.07 [0.16; 7.10]

Short-term non-fatal reinfarction 0.00 [0.00; NaN]

Short-term urgent target vessel revascularisation 0.00 [0.00; NaN]

Final TIMI 3 flow 1.08 [0.97; 1.20]

Initial TIMI 3 flow 1.61 [0.66; 3.94]

facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion (n=245)

vs.

primary intervention (n=247)

Sample size: 245/247

Primary endpoint:

FU duration: 30-day

facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion (n=50)

vs.

primary intervention (n=50)

Sample size: 50/50

Primary endpoint:

FU duration: 30-day

facilated PCI with Tirofiban; 10 µg/kg intravenous bolus, 0·15 µg/kg per min infusion (n=28)

vs.

primary intervention (n=30)

Sample size: 28/30

Primary endpoint:

FU duration: 30-day

loading dose 10µg/kg infusion 0.15µg/kg/min for 36h (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

loading dose µg/kg infusion µg/min for h (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: